MCID: HPT003
MIFTS: 60

Hepatitis a

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis a

MalaCards integrated aliases for Hepatitis a:

Name: Hepatitis a 12 75 43 44 15 17 72
Viral Hepatitis, Type a 12
Viral Hepatitis a 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12549
MeSH 44 D006506
NCIt 50 C3096
SNOMED-CT 68 40468003
ICD10 33 B15.0 B15.9
UMLS 72 C0019159

Summaries for Hepatitis a

MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis A, is caused by the hepatitis A virus (HAV). The disease spreads through contact with an infected person's stool. You can get it from Eating food made by an infected person who did not wash their hands after using the bathroom Drinking untreated water or eating food washed in untreated water Putting into your mouth a finger or object that came into contact with an infected person's stool Having close contact with an infected person, such as through sex or caring for someone who is ill Most people do not have any symptoms. If you do have symptoms, you may feel as if you have the flu. You may also have yellowish eyes and skin, called jaundice. A blood test will show if you have HAV. HAV usually gets better in a few weeks without treatment. However, some people can have symptoms for up to 6 months. Your doctor may suggest medicines to help relieve your symptoms. The hepatitis A vaccine can prevent HAV. Good hygiene can also help. Wash your hands thoroughly before preparing food, after using the toilet, or after changing a diaper. International travelers should be careful about drinking tap water. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis a, also known as viral hepatitis, type a, is related to acute liver failure and hepatitis, and has symptoms including fever, vomiting and fatigue. An important gene associated with Hepatitis a is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways and Complement and coagulation cascades. The drugs Emtricitabine and Neomycin have been mentioned in the context of this disorder. Affiliated tissues include liver, liver and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis A virus, which is transmitted by ingestion of contaminated food or water, or transmitted by direct contact with an infected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 75 Hepatitis A is an infectious disease of the liver caused by Hepatovirus A (HAV). Many cases have few or... more...

Related Diseases for Hepatitis a

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E

Diseases related to Hepatitis a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 623)
# Related Disease Score Top Affiliating Genes
1 acute liver failure 32.4 GPT F2 ALB
2 hepatitis 31.9 TNF MAVS HAVCR2 HAVCR1 GPT F2
3 hepatitis d 30.8 GPT F2
4 hepatitis e 30.8 TNF GPT F2 ALB
5 hepatic coma 30.8 GPT F2 ALB
6 typhoid fever 30.7 TNF F2 ALB
7 alcoholic hepatitis 30.6 TNF GPT F2 ALB
8 cholecystitis 30.6 GPT F2 ALB
9 viral hepatitis 30.5 TNF SERPINA1 GPT F2 ALB AFP
10 hepatitis b 30.4 TNF GPT F2 ALB AFP
11 bilirubin metabolic disorder 30.4 GPT F2 ALB
12 hepatic encephalopathy 30.3 TNF GPT F2 ALB
13 cholangitis 30.1 TNF GPT F2 ALB
14 purpura 30.1 TNF F3 F2
15 peritonitis 30.0 TNF F2 ALB
16 portal hypertension 29.9 TNF GPT F2 ALB
17 epstein-barr virus hepatitis 29.9 F2 ALB
18 esophageal varix 29.8 F2 ALB AFP
19 viral infectious disease 29.8 TNF MAVS GPT
20 infantile liver failure syndrome 1 29.8 GPT F2 ALB
21 chronic graft versus host disease 29.8 TNF ALB
22 wilson disease 29.7 GPT F2 ALB
23 endocarditis 29.7 TNF F2 ALB
24 opisthorchiasis 29.7 TNF GPT AFP
25 choledocholithiasis 29.6 GPT F2 ALB
26 schistosomiasis 29.5 TNF F2 ALB
27 eclampsia 29.5 TNF F2 ALB
28 obstructive jaundice 29.4 TNF GPT F2 ALB
29 liver disease 29.4 TNF SERPINA1 GPT F3 F2 ALB
30 arteries, anomalies of 29.3 TNF F3 ALB
31 bile duct disease 29.2 GPT F2 ALB AFP
32 bronchitis 29.2 TNF SERPINA1 ALB
33 scrub typhus 29.2 TNF GPT F3
34 liver cirrhosis 29.0 SERPINA1 GPT F3 F2 ALB AFP
35 respiratory failure 28.9 TNF SERPINA1 F3 ALB
36 vascular disease 28.9 TNF F3 F2 ALB
37 hepatic tuberculosis 28.9 SERPINA1 GPT F2 ALB
38 dengue hemorrhagic fever 28.7 TNF F3 F2 ALB
39 gastrointestinal system disease 28.5 TNF SERPINA1 F2 ALB AFP
40 fatty liver disease 11.3
41 gianotti crosti syndrome 11.2
42 stevens-johnson syndrome/toxic epidermal necrolysis 11.1
43 non-a-e hepatitis 10.6 F2 ALB
44 antipyrine metabolism 10.6 F2 ALB
45 hepatoportal sclerosis 10.6 GPT F2
46 cutaneous leishmaniasis 10.6
47 hepatoid adenocarcinoma 10.5 ALB AFP
48 adult dermatomyositis 10.5 TNF GPT
49 endometrial small cell carcinoma 10.5 F2 AFP
50 abdominal tuberculosis 10.5 F2 ALB

Graphical network of the top 20 diseases related to Hepatitis a:



Diseases related to Hepatitis a

Symptoms & Phenotypes for Hepatitis a

Symptoms:

12
  • fever
  • vomiting
  • fatigue
  • abdominal pain
  • jaundice
  • nausea
  • loss of appetite
  • joint pain
  • clay-colored bowel movements

UMLS symptoms related to Hepatitis a:


nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Hepatitis a:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 ABCB7 F2 F3 HSPA5 IKBKG MAVS
2 homeostasis/metabolism MP:0005376 9.96 ABCB7 AFP ALB F2 F3 HSPA5
3 digestive/alimentary MP:0005381 9.87 ALB F2 HSPA5 IKBKG MAVS TICAM1
4 mortality/aging MP:0010768 9.7 ABCB7 AFP ALB F2 F3 HAVCR2
5 liver/biliary system MP:0005370 9.63 ABCB7 AFP ALB IKBKG TICAM1 TNF
6 neoplasm MP:0002006 9.17 AFP ALB F3 HSPA5 IKBKG TICAM1

Drugs & Therapeutics for Hepatitis a

Drugs for Hepatitis a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 499)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
2
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
3
Ezetimibe Approved Phase 4 163222-33-1 150311
4
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
5
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
6
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
7
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
8
Methadone Approved, Illicit Phase 4 76-99-3 4095
9
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
10
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
11
Nelfinavir Approved Phase 4 159989-64-7 64143
12
Zidovudine Approved Phase 4 30516-87-1 35370
13
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
14
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
15
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
16
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
17
Cobicistat Approved Phase 4 1004316-88-4
18
rituximab Approved Phase 4 174722-31-7 10201696
19
Losartan Approved Phase 4 114798-26-4 3961
20
Citalopram Approved Phase 4 59729-33-8 2771
21
Metformin Approved Phase 4 657-24-9 4091 14219
22
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
23
Simethicone Approved Phase 4 8050-81-5
24
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
25
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
26
Adalimumab Approved Phase 4 331731-18-1 16219006
27
Etanercept Approved, Investigational Phase 4 185243-69-0
28
Lenograstim Approved, Investigational Phase 4 135968-09-1
29
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
30
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
31
Azathioprine Approved Phase 4 446-86-6 2265
32
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
33
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
34
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
35
Nevirapine Approved Phase 4 129618-40-2 4463
36
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
37
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
38
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
39
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
40
Interferon alfacon-1 Approved, Investigational Phase 4 118390-30-0 9554198
41
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
42
Mycophenolic acid Approved Phase 4 24280-93-1 446541
43
tannic acid Approved Phase 4 1401-55-4
44
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
45
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
46
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
47
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
48
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
49
Zinc Approved, Investigational Phase 4 7440-66-6 32051
50
Modafinil Approved, Investigational Phase 4 68693-11-8 4236

Interventional clinical trials:

(show top 50) (show all 2346)
# Name Status NCT ID Phase Drugs
1 Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
2 Comparative Immunogenicity Study of Two Live Attenuated Hepatitis A Vaccines Unknown status NCT03231605 Phase 4
3 A Study Comparing the Effectiveness of Two Different Vaccination Schedules of the Combined Hepatitis A and B Vaccine(Twinrix Adult1440/20) Unknown status NCT00216229 Phase 4
4 Immune Response to Pneumococcal Conjugate Vaccine in Adults Receiving Hepatitis A Vaccine at the Same Time Unknown status NCT01926860 Phase 4
5 Study to Identify Eligible Subjects Using Response Guided Therapy-Stopping Rule for Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults. Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
6 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
7 Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
8 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
9 Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study) Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
10 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
11 PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab Unknown status NCT02523547 Phase 4 Cavir;Baraclude
12 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
13 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
14 Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B Unknown status NCT01380951 Phase 4 telbivudine
15 A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin Unknown status NCT01439776 Phase 4
16 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
17 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
18 Immunogenicity and Safety of High-dose Hepatitis B Vaccine Among Drug Users: a Randomized, Controlled Trial Unknown status NCT02959775 Phase 4
19 A Randomized, Opened, Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Young Adults Unknown status NCT02203357 Phase 4
20 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
21 Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
22 AN OPEN STUDY OF LAMIVUDINE TREATMENT IN ADULT HBeAg NEGATIVE (Presumed Pre-Core Mutant) CHRONIC HEPATITIS B PATIENTS IN IRAN. Unknown status NCT00354653 Phase 4 LAMIVUDINE
23 Efficacy and Safety of Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir or Adefovir Monotherapy Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
24 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
25 A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
26 A Pilot Study Evaluating the Combination Hepatitis A and B Vaccine (Twinrix®) in Healthy Healthcare Workers Who Meet the CDC Definition for Non-responders. Unknown status NCT01126853 Phase 4
27 A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B: Unknown status NCT01456312 Phase 4 Peginterferon alfa-2a;Entecavir
28 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
29 The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
30 Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
31 Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
32 Immunogenicity and Persistence of Intramuscular High Dose Recombinant Hepatitis B Vaccine in Hemodialysis Patients in China: a Multicenter Randomized Controlled Trial Unknown status NCT02963714 Phase 4
33 Analysis of Proximal Renal Tubular Function of "Real World" Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF Unknown status NCT02957994 Phase 4 Tenofovir alafenamide fumarate
34 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
35 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
36 Immunogenicity and Reactogenicity of 10-valent Pneumococcal Conjugate Vaccine (PCV10) in Children Aged 12-59 Months Unknown status NCT01028326 Phase 4
37 A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection Unknown status NCT00939068 Phase 4 Telbivudine
38 Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
39 Tenofovir Disoproxil Fumarate in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus in Highly Viremic Mothers Unknown status NCT01488526 Phase 4 TDF treatment
40 A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
41 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
42 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
43 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
44 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
45 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
46 Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
47 A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
48 Immunologic Response of Hepatitis B Single Dose Versus 3-dose Series in Previously Vaccinated HIV-infected Adults at Maharaj Nakorn Chiang Mai Hospital: A Randomized Controlled Trial Unknown status NCT03219203 Phase 4
49 A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
50 Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)

Search NIH Clinical Center for Hepatitis a

Cochrane evidence based reviews: hepatitis a

Genetic Tests for Hepatitis a

Anatomical Context for Hepatitis a

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis a:

19
Liver

MalaCards organs/tissues related to Hepatitis a:

41
Liver, Testes, Kidney, T Cells, Bone, B Cells, Skin

Publications for Hepatitis a

Articles related to Hepatitis a:

(show top 50) (show all 11860)
# Title Authors PMID Year
1
Immunization recommendations against hepatitis A in Spain: Effectiveness of immunization in MSM and selection of antigenic variants - Authors' Reply. 38 17
31231017 2019
2
Plateletcrit: A possible biomarker of inflammation in hepatitis A infection. 38 17
31089030 2019
3
Sero-prevalence of viral hepatitis A in a district of Sri Lanka: a community based cross-sectional study. 38 17
31113369 2019
4
Persistence of murine norovirus, bovine rotavirus, and hepatitis A virus on stainless steel surfaces, in spring water, and on blueberries. 38
31421763 2019
5
Concentration of hepatitis A virus in milk using protamine-coated iron oxide (Fe3O4) magnetic nanoparticles. 38
31421754 2019
6
Fecal pollution source tracking and thalassogenic diseases: The temporal-spatial concordance between maximum concentrations of human mitochondrial DNA in seawater and Hepatitis A outbreaks among a coastal population. 38
31176815 2019
7
Missing the Match Might Not Cost You the Game: Primer-Template Mismatches Studied in Different Hepatitis A Virus Variants. 38
31004336 2019
8
Extended direct lysis method for virus detection on berries including droplet digital RT-PCR or real time RT-PCR with reduced influence from inhibitors. 38
30953663 2019
9
Household-based biodigesters promote reduction of enteric virus and bacteria in vulnerable and poverty rural area. 38
31146241 2019
10
Evaluation of the VIDAS hepatitis E IgM test in a nonendemic region. 38
31196687 2019
11
The regulatory actions of retinoic acid on M2 polarization of porcine macrophages. 38
30974109 2019
12
Identification of a functional nuclear localization signal in 3Dpol/3CD of duck hepatitis A virus 1. 38
31330206 2019
13
Characteristics associated with hepatitis A vaccination initiation and completion among adults traveling to a country of high or intermediate endemicity. 38
30879801 2019
14
Molecular Characterization and Phylogenetic Analysis of Enteroviruses and Hepatitis A Viruses in Sewage Samples, Northern Italy, 2016. 38
31420848 2019
15
A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure. 38
30194739 2019
16
Evaluation of the trends in the incidence of infectious diseases using the syndromic surveillance system, early warning and response unit, Mongolia, from 2009 to 2017: a retrospective descriptive multi-year analytical study. 38
31399064 2019
17
Update From the Advisory Committee on Immunization Practices. 38
31367738 2019
18
Severe dengue in travellers: pathogenesis, risk and clinical management. 38
31423536 2019
19
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. 38
31413005 2019
20
Readmission Rates and Associated Outcomes for Alcoholic Hepatitis: A Nationwide Cohort Study. 38
31372912 2019
21
Vaccinations in prison settings: A systematic review to assess the situation in EU/EEA countries and in other high income countries. 38
31327651 2019
22
Early Childhood Vaccination Status of Preterm Infants. 38
31391213 2019
23
Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study. 38
31427323 2019
24
Bacterial and Viral Investigations Combined with Determination of Phytoplankton and Algal Biotoxins in Mussels and Water from a Mediterranean Coastal Lagoon (Sardinia, Italy). 38
31411509 2019
25
Molecular Genotyping of Hepatitis A Virus, California, USA, 2017-2018. 38
31310213 2019
26
Commentary: Hepatitis: A way to make organ donation go viral? 38
31196756 2019
27
Homelessness and Hepatitis A - San Diego County, 2016-2018. 38
31412358 2019
28
Primary hepatic neuroendocrine carcinoma with massive hepatomegaly in a young-old woman. 38
31429180 2019
29
Direct Medical Costs of 3 Reportable Travel-Related Infections in Ontario, Canada, 2012-2014. 38
31310226 2019
30
Prevention of Opportunistic Infections in Women With HIV Infection. 38
31433312 2019
31
Establishment of a Simultaneous Detection Method for Ten Duck Viruses Using MALDI-TOF Mass Spectrometry. 38
31430495 2019
32
A conserved RNA structural motif for organizing topology within picornaviral internal ribosome entry sites. 38
31399592 2019
33
Infectious Disease Management and Control with Povidone Iodine. 38
31414403 2019
34
Safe supplies: few infections in UK blood and tissue donors. 38
30689250 2019
35
Immune dissociation during acute hepatitis E infection. 38
31408707 2019
36
Infectious Diseases pre-transplant evaluation improves vaccination rates for liver transplant candidates. 38
31419347 2019
37
The pathogenicity of duck hepatitis A virus types 1 and 3 on ducklings. 38
31393586 2019
38
Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study. 38
31396919 2019
39
Genetic association between mannose-binding lectin polymorphisms and viral hepatitis: a meta-analysis. 38
31381758 2019
40
NewsCAP: Increase in hepatitis A infections in parts of the United States. 38
31356311 2019
41
Asymptomatic giant cell hepatitis: a subtype of post-infantile giant cell hepatitis? 38
30767175 2019
42
Infectious mononucleosis (Epstein-Barr virus infection) and chronic hepatitis. 38
31257838 2019
43
Inherited IL-18BP deficiency in human fulminant viral hepatitis. 38
31213488 2019
44
Acute-onset Autoimmune Hepatitis in a Patient with Selective Immunoglobulin M Deficiency. 38
30996186 2019
45
Early Seroreversion After 2 Doses of Hepatitis A Vaccination in Human Immunodeficiency Virus-Positive Patients: Incidence and Associated Factors. 38
30614542 2019
46
Tubercular hemoptysis in a young liver transplanted patient: Case report. 38
31415374 2019
47
Diagnostic value of circulating miRNA⁃122 for hepatitis B virus and/or hepatitis C virus-associated chronic viral hepatitis. 38
31427483 2019
48
Metagenomic next-generation sequencing aids the diagnosis of viral infections in febrile returning travellers. 38
31398374 2019
49
A reverse transcription-insulated isothermal PCR assay for the detection of duck hepatitis A virus type 3 based on the POCKIT™ system. 38
31100286 2019
50
Hepatitis A outbreak affecting men who have sex with men (MSM) in central Argentina, occurred in July 2017-April 2018, later than the European outbreak. 38
31202104 2019

Variations for Hepatitis a

Expression for Hepatitis a

Search GEO for disease gene expression data for Hepatitis a.

GO Terms for Hepatitis a

Cellular components related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 TNF SERPINA1 GPT F3 F2 ALB
2 endoplasmic reticulum lumen GO:0005788 9.02 SERPINA1 HSPA5 F2 ALB AFP

Biological processes related to Hepatitis a according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.8 TNF TICAM1 IKBKG HAVCR2
2 cellular response to lipopolysaccharide GO:0071222 9.72 TNF TICAM1 HAVCR2
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.7 TNF TICAM1 IKBKG
4 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.54 TICAM1 IKBKG
5 positive regulation of chemokine production GO:0032722 9.51 TNF HAVCR2
6 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.5 TNF TICAM1 IKBKG
7 positive regulation of tumor necrosis factor secretion GO:1904469 9.48 MAVS HAVCR2
8 toll-like receptor 3 signaling pathway GO:0034138 9.46 TICAM1 HAVCR2
9 cellular protein metabolic process GO:0044267 9.46 SERPINA1 F2 ALB AFP
10 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.43 TICAM1 IKBKG
11 macrophage activation involved in immune response GO:0002281 9.4 TICAM1 HAVCR2
12 positive regulation of chemokine biosynthetic process GO:0045080 9.37 TNF TICAM1
13 positive regulation of myeloid dendritic cell cytokine production GO:0002735 9.26 TICAM1 MAVS
14 hemostasis GO:0007599 9.13 SERPINA1 F3 F2
15 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 8.92 TNF TICAM1 MAVS IKBKG

Molecular functions related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 8.8 TNF SERPINA1 F3

Sources for Hepatitis a

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....